CeriBell (NASDAQ:CBLL) Now Covered by JPMorgan Chase & Co.

JPMorgan Chase & Co. initiated coverage on shares of CeriBell (NASDAQ:CBLL) in a report issued on Tuesday, MarketBeat reports. The brokerage issued an overweight rating and a $32.00 price objective on the stock.

A number of other research analysts have also commented on CBLL. TD Cowen began coverage on CeriBell in a research report on Tuesday. They set a “buy” rating and a $31.00 price target for the company. William Blair assumed coverage on CeriBell in a report on Tuesday. They set an “outperform” rating for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $31.00.

CeriBell Price Performance

CBLL stock opened at $26.96 on Tuesday. CeriBell has a 12-month low of $23.00 and a 12-month high of $27.71.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.